Metalmark Capital completed a $50m investment in Morgenesis.

Metalmark Capital, a private equity firm, completed a $50m investment in Morgenesis, the point of care services subsidiary of Orgenesis. "We are excited to partner with Vered Caplan and the entire Morgenesis team. The company has built an impressive and differentiated point of care model which accelerates access for patients to innovative therapies, and we look forward to supporting Morgenesis as it continues to expand globally and in the United States," Howard Hoffen, Metalmark Chairman and CEO.